| Business Summary | | Exten
Industries,
Inc.
is
engaged
in
the
management
of
its
Xenogenics
Corp.
subsidiary's
proposed
research
and
development
activities
of
Sybiol
artificial
liver
technology.
The
Company
is
currently
working
toward
a
new
generation
device
for
liver
failure
treatment
and
an
engineered
cell
line
to
work
with
it.
An
NIH
grant
was
authorized
in
January
2001
to
help
fund
joint
research
between
Xenogenics,
MultiCell
Corporation
of
Rhode
Island
and
Compact
Membranes
of
Delaware.
When
the
product
redesign
work
with
these
and
other
research
partners
is
completed,
testing
is
expected
to
resume
at
Loyola
University
Medical
Center
and
other
sites.
The
FDA
approval
process
could
take
3
to
5
years. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Exten
Industries,
Inc.,
is
a
holding
company
that
is
in
the
business
of
developing,
through
its
wholly-owned
subsidiary,
Xenogenics
Corp.,
a
synthetic
bio-liver
technology.
For
the
six
months
ended
5/31/01,
the
Company
reported
no
revenues.
Net
loss
increased
37%
to
$481
thousand.
Higher
loss
reflects
increased
consulting
fee
and
general
and
administrative
expenses
and
increased
minority
interest
in
losses
of
subsidiary. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| W. Gerald Newmin, 63 Chairman,
CEO, Sec. | $48K | Gregory Szabo Pres,
Director | -- | Dollar amounts are as of 30-Nov-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|